Kory James Wentworth Sells 1,000 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) CFO Kory James Wentworth sold 1,000 shares of the company’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $19.97, for a total transaction of $19,970.00. Following the transaction, the chief financial officer now directly owns 73,849 shares of the company’s stock, valued at $1,474,764.53. This trade represents a 1.34 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Kory James Wentworth also recently made the following trade(s):

• On Monday, December 2nd, Kory James Wentworth sold 5,000 shares of Entrada Therapeutics stock. The shares were sold at an average price of $20.00, for a total value of $100,000.00.
• On Monday, November 11th, Kory James Wentworth sold 8,637 shares of Entrada Therapeutics stock. The shares were sold at an average price of $19.98, for a total transaction of $172,567.26.
• On Monday, September 9th, Kory James Wentworth sold 3,195 shares of Entrada Therapeutics stock. The shares were sold at an average price of $14.97, for a total value of $47,829.15.

Entrada Therapeutics Stock Performance

Shares of NASDAQ:TRDA traded down $0.15 during mid-day trading on Tuesday, hitting $20.17. The stock had a trading volume of 161,090 shares, compared to its average volume of 107,529. Entrada Therapeutics, Inc. has a 12-month low of $11.35 and a 12-month high of $20.50. The company has a market cap of $754.76 million, a PE ratio of 12.69 and a beta of -0.18. The company’s 50 day moving average is $17.70 and its 200-day moving average is $16.34.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Oppenheimer lifted their price target on Entrada Therapeutics from $25.00 to $28.00 and gave the company an “outperform” rating in a research report on Wednesday, November 6th. HC Wainwright raised their price objective on Entrada Therapeutics from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday, November 6th.

Institutional Trading of Entrada Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of TRDA. Janus Henderson Group PLC raised its position in Entrada Therapeutics by 10.5% during the third quarter. Janus Henderson Group PLC now owns 1,711,459 shares of the company’s stock valued at $27,358,000 after buying an additional 161,962 shares during the period. Vanguard Group Inc. grew its stake in Entrada Therapeutics by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 1,078,908 shares of the company’s stock valued at $15,288,000 after acquiring an additional 13,742 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Entrada Therapeutics by 8.8% in the 3rd quarter. Geode Capital Management LLC now owns 576,451 shares of the company’s stock valued at $9,214,000 after purchasing an additional 46,512 shares during the period. State Street Corp lifted its position in shares of Entrada Therapeutics by 5.5% in the third quarter. State Street Corp now owns 469,601 shares of the company’s stock worth $7,504,000 after purchasing an additional 24,385 shares in the last quarter. Finally, American Century Companies Inc. boosted its holdings in shares of Entrada Therapeutics by 5.1% during the second quarter. American Century Companies Inc. now owns 384,973 shares of the company’s stock worth $5,486,000 after purchasing an additional 18,625 shares during the period. Institutional investors and hedge funds own 86.39% of the company’s stock.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.